A genome-wide study using expression profiles of 12,600 genes was conducted to identify methylated genes that could be used for early diagnosis of hepatocellular carcinoma (HCC). Of the 12,600 genes examined, we identified 23 genes with significantly lower expression levels in HCC tissues than in non-HCC liver tissues by our statistical and CpG mapping tests. Of these 23 genes, methylation analysis by direct sequencing with bisulfite treatment determined 4 genes that were aberrantly methylated in 20 HCC samples of TNM stages I and II. Further methylation analysis of the 4 genes by quantitative sequencing with 20 HCCs and the corresponding non-tumor liver tissues from an independent cohort of HCC patients revealed that 2 genes, BASP1 and SRD5A2, were aberrantly methylated in only HCC tissues, though not in any corresponding non-tumor liver tissues. Notably, in the cohort we found that BASP1 or SRD5A2 were aberrantly methylated when a cut-off value of 30% in the methylation rate was used, in all cases of 11 HCCs of TNM stages I and II, of 10 welldifferentiated HCCs and of 4 small HCCs <2 cm in maximum diameter, but in none of the 20 corresponding non-HCC livers. Methylation-specific PCR for BASP1 and SRD5A2 reproduced the same results observed by direct sequencing. These results indicate that BASP1 and SRD5A2 might serve as useful biomarkers for early diagnosis of HCC.
Introduction
Hepatocellular carcinoma (HCC), which mainly develops from chronic liver diseases (chronic hepatitis and liver cirrhosis) with persistent infection of the hepatitis C virus (HCV) and hepatitis B virus (HBV), represents a major international health problem due to an increasing incidence in many countries (1, 2) . HCC is also one of the most common fatal cancers worldwide due to the fact that most cases are first diagnosed at an advanced stage since there is no reliable diagnostic test available for detecting HCC among high-risk individuals with chronic hepatitis and liver cirrhosis (1, 2) . Therefore, a simple and sensitive system for early diagnosis of HCC is urgently needed to improve the outcome of patients with HCC.
Previously, several investigators have proposed that epigenetic inactivation of gene expression linked to aberrant methylation on CpG islands is a fundamental contributor to carcinogenesis and cancer progression (3) (4) (5) . Previous clinical studies of the association between abnormal methylation on CpG islands and carcinogenesis have been conducted in various cancers including HCCs (6) (7) (8) (9) (10) (11) , supporting the concept that detection of methylation on particular genes in cancer cells may be useful for cancer diagnosis. However, it remains unclear if hypermethylation detection of those genes can be applied to routine clinical use for diagnosis of cancer because previous studies have been limited to looking at only tumor suppressor genes or genes associated with cell proliferation and death (6) (7) (8) (9) (10) (11) , which should be commonly related to carcinogenesis in various organs and tissues. This genomewide study was conducted to identify methylated genes suitable for use in early diagnosis of HCC in HCV-infected patients and to establish an easy-to-use methylation-specific PCR (MSP) system to measure the methylation status of such genes.
Identification of novel aberrant methylation of
BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search
Materials and methods

Patients and gene expression database.
For identification of novel HCC-specific methylation genes, we examined a 12,600-gene expression database (12) using the Affymetrix Human Genome U95A Gene Chip ® (Affymetrix, Inc., Santa Clara, CA), with surgical specimens of 76 tumor and 16 nontumor liver tissues in 76 patients who underwent surgical treatment for HCC at Yamaguchi University Hospital between May 1997 and August 2000. To examine the promoter methylation status of candidate genes in HCC samples that were selected in silico, we used genomic DNA from liver tissue samples of 40 HCC patients independent of the above 76 HCC patients who were subjected to DNA microarray analysis. Subsequently, the 40 HCC patients were divided into 2 subgroups; first round methylation profiling group and second round methylation profiling group (Table I) Table I . Written informed consent was obtained from all patients before surgery. The study protocol was approved by the Institutional Review Board for Human Use at Yamaguchi University School of Medicine. Histopathological diagnosis of HCC was made after surgery for each case.
Filtering of HCC-specific methylation candidate genes using the gene expression database. To filter HCC-specific methylation genes out of the ~12,600 in the gene expression database (12), we first selected genes whose signal strength (expression level) was specifically and significantly reduced to half or less in HCC tissues against non-tumor liver tissues by comparing gene expression levels between 76 HCC and 16 non-tumor liver tissues (p<0.05). The CpG islands on these genes should be most predominantly methylated in HCC. Then, among the down-regulated genes in HCC tissues, we selected genes carrying CpG islands in the regions, including promoter and exon 1 (defined as 1,500 bp upstream to 2,200 bp downstream from exon 1 start site, which also included up to 4,000 bp downstream for CYP2E1 which has no CpG island in the promoter) by CpG mapping analysis using the CpGPlot/ CpGReport/Isochore, a public tool at The European Bioinformatics Institute (EBI) in the European Molecular Biology Laboratory (EMBL) (http://www.ebi.ac.uk/emboss/ cpgplot/). The parameters were set as Obs/Exp (the minimum average observed to expected ratio of C plus G to CpG) = 0.6, MinPC (the minimum average percentage of G plus C) = 50, and Length (the minimum length that a CpG island has to be) = 100 bp.
Analysis of DNA methylation. For the candidate genes selected by filtering in silico, 1 μg of genomic DNA was extracted from tumor tissues of 20 patients with HCC of TNM stages I and II (first round methylation profiling group), as summarized in Table I . These extracted DNAs were treated with bisulfite (BIS) for 5 h at 50˚C to convert unmethylated cytosine to uracil, as described previously (14) (15) (16) . BIStreated DNA was quantified as described previously (16) and then was prepared with 75 μl of 10 mM Tris-HCl-0.1 mM EDTA solution. After BIS processing, the region including CpG islands on the candidate genes was amplified by PCR and the methylation status was examined by direct-sequencing using dideoxy chain termination method, using BIS-treated DNA for a template. During this first round methylation profiling, genes unmethylated or methylated poorly at CpG positions were eliminated from the gene candidate group. Furthermore, of the genes hypermethylated at CpG positions in HCC samples, genes that were found to be highly methylated in normal liver tissues from healthy individuals were excluded as well. Methylation profiles of the remaining genes were further investigated by pyrosequencing (17) , a quantitative sequencing method using the Pyrosequencer PSQ96MA and the Pyro Gold Reagents (Biotag AG, Uppsala, Sweden), in the 20 tumor and the corresponding non-tumor liver tissues from other 20 HCC patients (second round methylation profiling group; see Table I ), liver tissues from 2 HCV carriers with chronic hepatitis and liver tissues from 3 healthy individuals. The pyrosequencing results are shown as a Pyrogram (Fig. 1) . The methylation rate (%) at each CpG position is given by the formula, peak height of Cytosine/(peak height of Cytosine + peak height of thymine) x 100. Furthermore, the average of methylation rates at all the examined CpG positions on candidate genes for each sample was calculated. Genes that had higher average methylation rates in tumor tissues of HCC patients than in both non-tumor liver tissues of HCC patients and liver tissues of HCV carriers, were finally judged as HCC-specific methylation genes. The selected genes were only slightly methylated in liver tissues of healthy individuals as well as in those of HCV carriers.
PCR amplification of CpG island regions.
For sequencing analysis, the region containing CpG islands of each gene was amplified by PCR with a primer set listed in Table II . The PCR reaction solution was composed of 26.7 ng of BIS-treated DNA, 2 units of rTaq DNA polymerase (Toyobo Co., Ltd, Osaka, Japan) which was pretreated with the equal volume of TaqStart™Antibody (Clontech Laboratories, Inc., Mountain View, CA) for 5 min at room temperature, 67 mM Tris-HCl (pH 8.8), 16.6 mM ammonium sulfate, 0.01% Tween-20, 200 μM dNTPs, each 1 μM of a primer pair and 1.5 or 3 mM magnesium chloride in a final volume of 100 μl. DNA amplification was performed by using the GeneAmp PCR system 9600 (Applied Biosystems, Foster City, CA) as a PCR amplification instrument by initial denaturation at 95˚C for 2 min followed by 5 cycles of denaturation at 95˚C for 25 sec, annealing at 70˚C for 45 sec, extension at 72˚C for 45 sec and followed by 50 cycles of denaturation at 95˚C for 25 sec, annealing at 55˚C for 50 sec, extension at 72˚C for 45 sec.
The PCR products (351-495 bp) were concentrated using the SUPREC™-02 (Takara Bio Inc., Otsu, Shiga, Japan) and subjected to electrophoresis on 2% agarose gel. The target bands of amplified products were excised from gel and isolated using the QIAquick Gel Extraction kit (Qiagen GmbH, Hilden, Germany).
Methylation-specific PCR. Methylation patterns of HCCspecific methylation genes were also confirmed by quantitative real-time methylation-specific PCR (MSP). Briefly, PCR amplification using a primer pair specific to the nucleotide sequence containing methylated cytosines at CpG positions was performed using the LightCycler ® Taq Man master kit for an amplification reagent and the LightCycler ® II (Roche Diagnostics GmbH, Mannheim, Germany) for a nucleic acid amplification instrument. For the BASP1 gene, the PCR reaction mixture was composed of 5 μl of diluted BIS-treated DNA (1 ng), 0.25 μM of a primer pair (Forward: 5'-TGTTCGTTTTTTTAGGGTATTC-3', Reverse: 5'-AATT AACCGAAACAACCCG-3') and 0.1 μM of Taq Man probe (5'-FAM-ACGCTACTACTTACGAACGCTCGAA-TAMRA-3') in a final volume of 20 μl of 1x Master mix. PCR amplification was carried out by initial denaturation at 95˚C for 10 min followed by 50 cycles of 95˚C for 10 sec, 63˚C for 45 sec and 72˚C for 5 sec followed by warming of 40˚C for 30 sec. Fluorescent signal was detected after extension reaction at 72˚C for each cycle. Amplification of the target gene was monitored by F1/F3 analysis mode in LightCycler software and the amount of methylated DNA in 75 μl of BIS-treated DNA solution was quantified using a standard curve made with simultaneously measured standards (dilution series of artificially methylated DNA: at 1000, 200, 40 and 4 pg/μl). As for the SRD5A2 gene, the PCR reaction mixture was composed of 5 μl of diluted BIS-treated DNA (1 ng), 0.2 μl of 2 M potassium acetate (pH 7.5), 0.04 μl of Aptamer 48, 50 mM tricine (pH 8.3), 3 mM magnesium acetate, 375 μM dNTPs, 2.5% glycerol, 0.15 unit ZO5 (thermostable DNA polymerase), 0.4 μM of a primer pair (Forward: 5'-AATCGCGTTAGGGTTGGACGC-3', Reverse: 5'-AACGCCAAACGCCACCCG-3') and 0.05 μM of Taq Man probe (5'-FAM-ACTCGACCTTAACTCCCGCCCCT-TAMRA-3') in a final volume of 20 μl. PCR amplification was carried out by initial denaturation at 95˚C for 2 min, followed by 50 cycles of 95˚C for 15 sec, 66˚C for 45 sec and 72˚C for 5 sec, followed by warming of 40˚C for 30 sec. After amplification, the amount of methylated DNA in 75 μl of BIS-treated DNA solution was quantified using a standard curve that was made with simultaneously measured standards (dilution series of artificially methylated DNA: at 1000, 200, 50 and 8 pg/μl). Table I . Patient characteristics in this study. 
a These samples were used for the construction of the gene expression database for selection of HCC-specific methylation candidate genes, which were down-regulated specifically in HCC tissues. b These samples were used for 1st round methylation profiling and aberrantly methylated genes in early-stage HCC of TNM stages I and II were selected by the analysis. c These samples were used for 2nd round methylation profiling and specifically methylated genes in HCC tissues but not non-tumor liver tissues and liver tissues of the HCV carrier were selected by the analysis.
- 
Results
Novel HCC-specific methylation genes, BASP1 and SRD5A2. Of the ~12,600 genes on the Affymetrix chip, only 101 (0.8%)
were differentially expressed between HCC tissues and non-tumor liver tissues. Out of these 101 genes, 23 (0.18%) carrying CpG islands in the regions containing promoter and exon 1 were chosen in silico by CpG mapping analysis (Table II) . These genes were then subjected to the methylation profiling step. Among the 23 HCC-specific methylation gene candidates, 6 genes which were identified as aberrantly methylated genes in HCC, ABCC9 (ATP-binding cassette, sub-family C, member 9), APOF (apolipoprotein F), BASP1 (brain abundant, membrane attached signal protein 1), GLS2 (glutaminase 2), HAL (histidine ammonia-lyase) and SRD5A2 Table I ) were employed for the analysis. As a reference, normal liver tissues from 3 healthy individuals (NL1-NL3) were also analyzed. Methylation rates are shown in different colors (red >75%, orange 75-50%, pale orange 50-30% and white <30%). Position of bisulfite sequencing region was given relative to exon 1 start site. (steroid-5-α-reductase, α polypeptide 2), were selected in the first round methylation profiling performed using methylation analysis of CpG islands on genomic DNAs in tumor tissues from 20 patients with HCC of TNM stages I and II. The six genes were further examined in liver tissues from 3 healthy individuals. From this analysis, APOF and GLS2 were excluded due to hypermethylation in normal liver tissues (data not shown). Then, in the second round methylation profiling by comparing methylation profiles of 20 tumor and the corresponding non-tumor liver tissues (12 liver cirrhosis, 7 chronic hepatitis and 1 normal liver) from other 20 HCC patients, liver tissues from 2 HCV carriers with chronic hepatitis and normal liver tissues from healthy individuals, ABCC9 was eliminated because the methylation patterns of tumor tissues of HCC patients were indistinguishable from those of non-tumor liver tissues of HCC patients and the liver tissues of HCV carriers, as shown in Fig. 2a and b. Furthermore, HAL was also excluded due to a much higher methylation rate (p<0.00005) (Fig. 2b ) in non-tumor liver tissues relative to tumor tissues of HCC patients, although this gene was at least more frequently methylated in HCC tissues, than in normal liver tissues from healthy individuals (Fig. 2a) . The remaining two genes, BASP1 and SRD5A2, fulfilled the criterion of the HCC-specific methylation gene, because of the definite difference in the extent of methylation of the genes between tumor and non-tumor liver tissues from HCC patients (p<0.00005) ( Fig. 2a and b) . These 2 genes were also not extensively methylated in liver tissues of HCV carrier and healthy individuals, with only slight methylation observed on a small part of the CpG positions (Fig. 2a) . In addition, the aberrant methylation of BASP1 or SRD5A2 was positive in 11 (100%) of 11 HCCs of TNM stages I and II, 10 (100%) of 10 well-differentiated HCCs and 4 (100%) of 4 small HCCs of <2 cm in maximum diameter, when a cut-off value of 30% in methylation rate was used in a new cohort of 20 HCC patients (Fig. 2b) . By contrast, the aberrant methylation of the 2 genes was not detected in any of the corresponding non-tumor liver tissues (Fig. 2b ). There were no significant associations among HCC methylation rates for the 4 genes (BASP1, SRD5A2, ABCC9 and HAL) and gender, age, tumor differentiation, tumor size, tumor number or TNM stages (data not shown).
Methylation analysis by MSP. We confirmed methylation status by quantitative real-time MSP for 19 samples (9 sets of tumor and the corresponding non-tumor liver tissues and 1 tumor tissue from 10 HCC patients) that were analyzed by pyrosequencing and examined the correlation between the methylation status analyzed by sequencing and MSP. By Pearson's test the methylated DNA concentration in 75 μl of BIS-treated DNA solution measured by MSP was shown to be strongly and significantly correlated with the methylation rate estimated by sequencing analysis (r=0.793, p<0.0001 and r=0.671, p<0.005 for BASP1 and SRD5A2, respectively) (Fig. 3) .
Discussion
We have successfully identified 2 aberrantly methylated genes, BASP1 and SRD5A2, associated with HCC by genome-wide search using gene expression profiles on the Affymetrix GeneChip. To our knowledge, this is the first study screening comprehensively to identify methylated genes for early diagnosis of HCC. Our strategy is justified by the finding that only 2 of 12,600 genes (0.016%) fulfilled our selection criteria and neither of the 2 genes have been reported as methylated genes in HCC. BASP1 was originally identified as a membrane bound protein that is abundant in nerve terminals, with several transient phosphorylation sites and PEST [regions rich in proline (P), glutamate (E) and/or aspartate (D) and serine (S) and/or threonine (T)] motifs that typically occur in proteins with high turnover rates (18) . It has also been reported to be a transcriptional cosuppressor for Wilms' tumor suppressor protein WT1 (19) , however, so far there has been no report Table II . The 23 genes whose expression level reduced to half or less in HCC tissues against non-tumor liver tissues.
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that this protein is correlated with pathogenesis of liver cancer. SRD5A2 encodes a microsomal protein expressed at high levels in androgen-sensitive tissues such as the prostate. The encoded protein is a membrane-associated enzyme that catalyzes the conversion of testosterone to dihydrotestosterone (DHT), the most potent androgen in the prostate and the polymorphism and expression level has been shown to be functionally associated with prostate cancer (20) (21) (22) . To date, it was reported that the SRD5A2 polymorphism could be associated with liver cancer (23), but no study has been done regarding methylation status in liver tissues. Thus, in this study we were the first to be able to show that BASP1 and SRD5A2 are exclusively methylated in tumor, but not non-tumor liver tissues from HCC patients and not methylated in any non-tumor liver tissues from HCV carriers. This suggests that BASP1 and SRD5A2 could be robust biomarkers for diagnosing correctively hepatic nodules arising in HCV-infected patients to be at-risk for HCC. These 2 genes were originally found to be methylated to a certain extent in liver tissues from healthy individuals (Fig. 2a) , as reported for some genes by Lehmann et al (11) . However, the slightly methylated status was observed to be similar to that of non-tumor and HCV carrier liver tissues in our study. This means BASP1 and SRD5A2 may undergo abnormal methylation only after, or concurrently with developing HCC, regardless of inflammation or fibrosis by HCV infection. It is well known that epigenetic changes, including methylation, are related to aging (24) . In our present study, no associations were observed between patient age and the methylation status of BASP1 and SRD5A2. This result might be due in part to the sample size of our present study. To gain insights into our present finding, larger studies are needed.
In our gene expression analysis, expression level of SRD5A2 in HCC tissues was reduced to one-fifth of that in non-tumor liver tissues (Table II) , which should be similar to the level found in normal liver tissues from healthy individuals (25) . This entrainment profile between high methylation and suppressed gene expression level suggests that SRD5A2 gene expression would be entirely epigenetically inactivated by abnormal methylation of CpG islands. BASP1 was relatively highly expressed in non-tumor liver tissues in our gene expression profiles (Table II) , though it has been reported that this gene was not expressed in liver by Western blot analysis (19) . Therefore, it could be that mRNA is transcribed, but undergoes only limited translation to protein, possibly due to causes such as fast turnover of mRNA in liver. Expression levels of BASP1 in tumor liver were reduced to half of those found in non-tumor liver (Table II) . This may imply that gene expression is not strongly suppressed by methylation. Indeed, our methylation profiling showed that BASP1 was not extensively methylated on CpG islands, even in HCC tissues, although it was at least more methylated than in non-tumor liver tissues of HCC patients, liver tissues of HCV carriers and normal liver tissues of healthy individuals (Fig. 2a) .
ABCC9 and HAL were eliminated through the selection process of HCC-specific methylation genes. Since the 2 genes were found to be strongly methylated in non-HCC tissues and liver tissues of HCV carriers as well as in HCC tissues, although they were not highly methylated in normal liver samples ( Fig. 2a and b) . For ABCC9, the methylation rate in HCC appeared to be slightly higher than in non-HCC, but they were not statistically different from each other. Interestingly, the methylation rate for HAL in non-HCC was significantly higher than in HCC as shown in Fig. 2b  (p<0.00005) . It is inferred from these results that ABCC9 and HAL may be methylated with development or progression of chronic liver diseases with HCV infection. Furthermore, HAL may undergo demethylation with carcinogenesis.
Most HCCs are initiated as a minute nodule in which cells strongly retain the phenotype of benign hepatocytes. Dysplastic changes, which would mark the transition to a small, welldifferentiated HCC, usually occur when the nodules measure between 1 and 2 cm in maximal diameter and herald the ability to proliferate, invade and disseminate (26) . At this stage, the tumors are easily detected by imaging techniques such as ultrasonography and computed tomography. However, it is not easy to discriminate pathologically well-differentiated HCC from other benign tumors such as dysplasia. Accordingly, the best way for an accurate early diagnosis of this cancer might be to identify the molecular changes that govern the transition to cancer. In this regard, the efficacy of BASP1 and SRD5A2 as tools for early diagnosis of HCC was shown by our present findings that they were aberrantly methylated in all cases of 11 HCCs of TNM stages I and II, of 10 well-differentiated HCCs and of 4 small HCCs <2 cm in maximum diameter. Additionally, our developed MSP has made it possible to easily quantify the methylation status of the 2 genes and may enable an early detection of HCC by measuring methylation levels in cell-free DNA circulating in the peripheral blood, although larger studies are needed to evaluate prospectively the diagnostic accuracy of these biomarkers prior to the blood test.
